US Patent

US9717740 — Treatment of adrenal insufficiency

Method of Use · Assigned to Diurnal Ltd · Expires 2032-11-19 · 7y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method of treating adrenal insufficiency, particularly in pediatric patients, the elderly, and non-human animals.

USPTO Abstract

The disclosure relates to the treatment of adrenal insufficiency with particular but not limiting application to pediatric treatment regimens, the treatment of the elderly and non-human animals.

Drugs covered by this patent

Cortef (hydrocortisone) · Generic (originally Merck/Upjohn)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3075`	—	Cortef
`U-3075`	—	Cortef
`U-3075`	—	Cortef
`U-3075`	—	Cortef

Patent Metadata

Patent number: US9717740
Jurisdiction: US
Classification: Method of Use
Expires: 2032-11-19
Drug substance claim: No
Drug product claim: No
Assignee: Diurnal Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.